JP5167446B2 - ブプレノルフィン誘導体及びその使用 - Google Patents

ブプレノルフィン誘導体及びその使用 Download PDF

Info

Publication number
JP5167446B2
JP5167446B2 JP2009502210A JP2009502210A JP5167446B2 JP 5167446 B2 JP5167446 B2 JP 5167446B2 JP 2009502210 A JP2009502210 A JP 2009502210A JP 2009502210 A JP2009502210 A JP 2009502210A JP 5167446 B2 JP5167446 B2 JP 5167446B2
Authority
JP
Japan
Prior art keywords
buprenorphine
acid
ether
mol
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009502210A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009531406A (ja
JP2009531406A5 (enExample
Inventor
クリストファー ボーン シャプレオ
ジョン ウィリアムズ ルイス
Original Assignee
アールビー ファーマシューティカルズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アールビー ファーマシューティカルズ リミテッド filed Critical アールビー ファーマシューティカルズ リミテッド
Publication of JP2009531406A publication Critical patent/JP2009531406A/ja
Publication of JP2009531406A5 publication Critical patent/JP2009531406A5/ja
Application granted granted Critical
Publication of JP5167446B2 publication Critical patent/JP5167446B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2009502210A 2006-03-28 2007-03-27 ブプレノルフィン誘導体及びその使用 Expired - Fee Related JP5167446B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0606124.6 2006-03-28
GBGB0606124.6A GB0606124D0 (en) 2006-03-28 2006-03-28 Buprenorphine derivatives and uses thereof
PCT/GB2007/001120 WO2007110636A1 (en) 2006-03-28 2007-03-27 Buprenorphine derivatives and uses thereof

Publications (3)

Publication Number Publication Date
JP2009531406A JP2009531406A (ja) 2009-09-03
JP2009531406A5 JP2009531406A5 (enExample) 2010-05-13
JP5167446B2 true JP5167446B2 (ja) 2013-03-21

Family

ID=36384277

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009502210A Expired - Fee Related JP5167446B2 (ja) 2006-03-28 2007-03-27 ブプレノルフィン誘導体及びその使用

Country Status (21)

Country Link
US (1) US7964610B2 (enExample)
EP (1) EP2001891B1 (enExample)
JP (1) JP5167446B2 (enExample)
KR (1) KR101430626B1 (enExample)
CN (2) CN104151320A (enExample)
AU (1) AU2007231133B2 (enExample)
BR (1) BRPI0709157A8 (enExample)
CA (1) CA2647417C (enExample)
DK (1) DK2001891T3 (enExample)
ES (1) ES2432169T3 (enExample)
GB (1) GB0606124D0 (enExample)
IL (1) IL193917A (enExample)
MX (1) MX2008011984A (enExample)
MY (1) MY151025A (enExample)
NZ (1) NZ570997A (enExample)
PL (1) PL2001891T3 (enExample)
PT (1) PT2001891E (enExample)
RU (1) RU2435773C2 (enExample)
TW (1) TWI501969B (enExample)
WO (1) WO2007110636A1 (enExample)
ZA (1) ZA200807614B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2549115T3 (es) 2006-09-22 2015-10-23 Zynerba Pharmaceuticals, Inc. Profármacos de buprenorfina administrables por vía transdérmica y composiciones resistentes al consumo excesivo de los mismos
US20110053971A1 (en) * 2008-04-24 2011-03-03 Janssen Pharmaceutica Nv Nalmefene di-ester prodrugs
FR2975912B1 (fr) 2011-05-30 2013-06-14 Flamel Tech Sa Composition a liberation controlee de buprenorphine
CA3002082A1 (en) * 2015-10-26 2017-05-04 Orphomed, Inc. Ethylene glycol ether of buprenorphine
EP3426234A1 (en) 2016-03-09 2019-01-16 Indivior UK Limited Abuse-resistant pharmaceutical formulations
PL3512518T3 (pl) 2016-09-13 2023-03-27 Alar Pharmaceuticals Inc. Preparaty buprenorfiny o przedłużonym uwalnianiu
WO2019064026A1 (en) 2017-09-29 2019-04-04 Orexo Ab NEW PHARMACEUTICAL COMPOSITIONS
TWI838372B (zh) 2018-05-11 2024-04-11 昱展新藥生技股份有限公司 丁基原啡因衍生物之長效注射劑型及結晶型
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
WO2023102489A1 (en) * 2021-12-03 2023-06-08 Board Of Regents Of The University Of Nebraska Compounds, nanoparticles, and pharmaceutical compositions for the treatment of drug addiction
CN116283893B (zh) * 2023-03-22 2024-04-26 阜阳欣奕华制药科技有限公司 硫代羟基乙酸酐的制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
GB8728294D0 (en) * 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5985880A (en) * 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
US5750534A (en) * 1994-03-16 1998-05-12 National Science Council Nalbuphine esters having long acting analgesic action and method of use
US6004969A (en) * 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
KR100204659B1 (ko) * 1996-05-28 1999-06-15 강재헌 신규한 부프레노핀계 진통제용 화합물
US6225321B1 (en) * 1997-06-05 2001-05-01 Oliver Yoa-Pu Hu Long analgesic acting nalbuphine polyester derivative and method of use
CN1150895C (zh) 1998-11-13 2004-05-26 杰格研究股份公司 用于吸入给药的干粉
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
SI2283842T1 (sl) * 2000-02-08 2015-07-31 Euro-Celtique S.A. Oralne formulacije opioidnih agonistov, varne pred zlorabo
WO2003026743A2 (en) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US7776314B2 (en) * 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
EP1554290B1 (en) * 2002-10-25 2009-09-30 Euro-Celtique S.A. Analogs and prodrugs of buprenorphine
DE10250084A1 (de) * 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10250087A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20050186139A1 (en) * 2002-10-25 2005-08-25 Gruenenthal Gmbh Abuse-proofed dosage form
US20050191244A1 (en) * 2002-10-25 2005-09-01 Gruenenthal Gmbh Abuse-resistant pharmaceutical dosage form
RU2215741C1 (ru) * 2002-11-05 2003-11-10 Открытое Акционерное Общество "Международная Научно-Технологическая Корпорация" Сложные эфиры n-замещенных 14-гидроксиморфинанов и способ их получения
CN1263760C (zh) * 2002-11-12 2006-07-12 财团法人奇美医院 新颖的丁丙诺啡酯衍生物及其制备方法，以及长效作用镇痛药学组合物
ATE382050T1 (de) * 2002-11-25 2008-01-15 Chi Mei Foundation Medical Ct Buprenorphinesterderivate, verfahren zu ihrer herstellung, und langwirksame analgetische arzneimittel
JP2004175706A (ja) * 2002-11-26 2004-06-24 Chi Mei Foundation Medical Center 新規なブプレノルフィンのエステル誘導体及びそれらの調製方法、及び長時間効力持続性鎮痛薬剤組成物
TW200500067A (en) * 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
WO2004071491A1 (en) * 2003-02-04 2004-08-26 Chrysalis Technologies Incorporated Aerosol formulations and aerosol delivery of buspirone, buprenorphine, triazolam, cyclobenzaprine and zolpidem
US7195882B2 (en) * 2003-06-03 2007-03-27 Roche Diagnostics Operations, Inc. Monoclonal antibodies specific for buprenorphine and metabolites thereof
WO2005009377A2 (en) * 2003-07-23 2005-02-03 University Of Kentucky Research Foundation Novel oral bioavailable prodrugs
US7589233B2 (en) * 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US7220842B2 (en) * 2004-04-05 2007-05-22 Dade Behring Inc. Immunoassays for buprenorphine and norbuprenorphine

Also Published As

Publication number Publication date
GB0606124D0 (en) 2006-05-03
KR101430626B1 (ko) 2014-08-18
BRPI0709157A8 (pt) 2018-04-24
TWI501969B (zh) 2015-10-01
ES2432169T3 (es) 2013-12-02
AU2007231133B2 (en) 2011-09-01
EP2001891B1 (en) 2013-07-24
PL2001891T3 (pl) 2014-03-31
CN101410402A (zh) 2009-04-15
CN104151320A (zh) 2014-11-19
JP2009531406A (ja) 2009-09-03
US7964610B2 (en) 2011-06-21
US20100234412A1 (en) 2010-09-16
RU2435773C2 (ru) 2011-12-10
IL193917A (en) 2014-12-31
TW200806672A (en) 2008-02-01
MX2008011984A (es) 2008-10-03
ZA200807614B (en) 2009-10-28
BRPI0709157A2 (pt) 2011-06-28
AU2007231133A2 (en) 2008-10-16
CA2647417C (en) 2014-09-23
NZ570997A (en) 2011-08-26
DK2001891T3 (da) 2013-11-04
AU2007231133A8 (en) 2011-08-25
PT2001891E (pt) 2013-10-30
MY151025A (en) 2014-03-31
RU2008142527A (ru) 2010-05-10
WO2007110636A1 (en) 2007-10-04
AU2007231133A1 (en) 2007-10-04
EP2001891A1 (en) 2008-12-17
KR20080105124A (ko) 2008-12-03
CA2647417A1 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
JP2009531406A (ja) ブプレノルフィン誘導体及びその使用
US7230005B2 (en) Compounds and methods for lowering the abuse potential and extending the duration of action of a drug
US8362007B1 (en) Substituted noribogaine
AU784541B2 (en) Novel methods and compositions involving opioids and antagonists thereof
RU2167152C2 (ru) N-замещенные азагетероциклические карбоновые кислоты или их фармацевтически приемлемые соли, способ их получения, фармацевтическая композиция на их основе и способ ингибирования нейрогенного воспаления
JP2010511717A (ja) プロドラッグおよびその作成ならびに使用方法
US20150361080A1 (en) Substituted noribogaine
US5925649A (en) Ascomycins
EP1782834A2 (en) Oxycodone conjugates with lower abuse potential and extended duration of action
US5750534A (en) Nalbuphine esters having long acting analgesic action and method of use
JP2002501923A (ja) 治療用化合物
AU2024289343A1 (en) Treprostinil derivative, and preparation method therefor and use thereof
KR20080081057A (ko) 진해제
EP1118324A1 (en) Analgesic agent comprising a cyclobutanedicarboxylic acid derivative
US8389551B2 (en) Optical enantiomers of phenyramidol and process for chiral synthesis
HK1130259A (en) Buprenorphine derivatives and uses thereof
JPH0341458B2 (enExample)
US10975099B2 (en) Thiophene compounds for long-acting injectable compositions and related methods
HK40114273A (en) Treprostinil derivative, and preparation method and use thereof
US20090182016A1 (en) Optical enantiomers of phenyramidol and process for chiral synthesis
SK7162002A3 (en) 2-arylquinoline derivatives, preparation and therapeutic use thereof
JPS635028B2 (enExample)
JPH092950A (ja) 医薬組成物および処置法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100325

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120903

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20120924

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121207

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees